Literature DB >> 28031364

An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.

Kathleen McCaffrey1,2,3, Irene Boo1, Catherine M Owczarek4, Matthew P Hardy4, Matthew A Perugini5, Louis Fabri4, Pierre Scotney4, Pantelis Poumbourios1,6, Heidi E Drummer7,6,2.   

Abstract

The hepatitis C virus (HCV) envelope glycoprotein E2 is the major target of broadly neutralizing antibodies in vivo and is the focus of efforts in the rational design of a universal B cell vaccine against HCV. The E2 glycoprotein exhibits a high degree of amino acid variability which localizes to three discrete regions: hypervariable region 1 (HVR1), hypervariable region 2 (HVR2), and the intergenotypic variable region (igVR). All three variable regions contribute to immune evasion and/or isolate-specific structural variations, both important considerations for vaccine design. A high-resolution structural definition of the intact HCV envelope glycoprotein complex containing E1 and E2 remains to be elucidated, while crystallographic structures of a recombinant E2 ectodomain failed to resolve HVR1, HVR2, and a major neutralization determinant adjacent to HVR1. To obtain further information on E2, we characterized the role of all three variable regions in E2 ectodomain folding and function in the context of a recombinant ectodomain fragment (rE2). We report that removal of the variable regions accelerates binding to the major host cell receptor CD81 and that simultaneous deletion of HVR2 and the igVR is required to maintain wild-type CD81-binding characteristics. The removal of the variable regions also rescued the ability of rE2 to form a functional homodimer. We propose that the rE2 core provides novel insights into the role of the variable motifs in the higher-order assembly of the E2 ectodomain and may have implications for E1E2 structure on the virion surface. IMPORTANCE Hepatitis C virus (HCV) infection affects ∼2% of the population globally, and no vaccine is available. HCV is a highly variable virus, and understanding the presentation of key antigenic sites at the virion surface is important for the design of a universal vaccine. This study investigates the role of three surface-exposed variable regions in E2 glycoprotein folding and function in the context of a recombinant soluble ectodomain. Our data demonstrate the variable motifs modulate binding of the E2 ectodomain to the major host cell receptor CD81 and have an impact on the formation of an E2 homodimer with high-affinity binding to CD81.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD81 receptor; glycoproteins; hepatitis C virus

Mesh:

Substances:

Year:  2017        PMID: 28031364      PMCID: PMC5309951          DOI: 10.1128/JVI.01668-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Authors:  R J Center; P L Earl; J Lebowitz; P Schuck; B Moss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Authors:  Leopold Kong; David E Lee; Rameshwar U Kadam; Tong Liu; Erick Giang; Travis Nieusma; Fernando Garces; Netanel Tzarum; Virgil L Woods; Andrew B Ward; Sheng Li; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

3.  CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs.

Authors:  K Kitadokoro; D Bordo; G Galli; R Petracca; F Falugi; S Abrignani; G Grandi; M Bolognesi
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

4.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Authors:  Zhen-yong Keck; Christine Girard-Blanc; Wenyan Wang; Patrick Lau; Adam Zuiani; Felix A Rey; Thomas Krey; Michael S Diamond; Steven K H Foung
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

8.  Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry.

Authors:  Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

9.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

10.  Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Authors:  Zhen-Yong Keck; Jinming Xia; Zhaohui Cai; Ta-Kai Li; Ania M Owsianka; Arvind H Patel; Guangxiang Luo; Steven K H Foung
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more
  9 in total

1.  Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.

Authors:  Vijayamahantesh Vijayamahantesh; Tapas Patra; Keith Meyer; Mohamad-Gabriel Alameh; Erin K Reagan; Drew Weissman; Ranjit Ray
Journal:  J Virol       Date:  2022-05-25       Impact factor: 6.549

Review 2.  Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review).

Authors:  Qianqian Zhao; Kun He; Xiuhua Zhang; Mingjie Xu; Xiuping Zhang; Huanjie Li
Journal:  Exp Ther Med       Date:  2022-05-30       Impact factor: 2.751

3.  Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.

Authors:  Johnathan D Guest; Ruixue Wang; Khadija H Elkholy; Andrezza Chagas; Kinlin L Chao; Thomas E Cleveland; Young Chang Kim; Zhen-Yong Keck; Alexander Marin; Abdul S Yunus; Roy A Mariuzza; Alexander K Andrianov; Eric A Toth; Steven K H Foung; Brian G Pierce; Thomas R Fuerst
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

Review 4.  Hepatitis C virus vaccine design: focus on the humoral immune response.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  J Biomed Sci       Date:  2020-07-06       Impact factor: 8.410

Review 5.  Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.

Authors:  Jannick Prentoe; Jens Bukh
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

6.  Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.

Authors:  Melanie R Walker; Auda A Eltahla; Michael M Mina; Hui Li; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2020-01-08       Impact factor: 5.048

Review 7.  Hepatitis C Virus Vaccine: Challenges and Prospects.

Authors:  Joshua D Duncan; Richard A Urbanowicz; Alexander W Tarr; Jonathan K Ball
Journal:  Vaccines (Basel)       Date:  2020-02-17

Review 8.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 9.  Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.

Authors:  Christopher C Phelps; Christopher M Walker; Jonathan R Honegger
Journal:  Viruses       Date:  2021-07-13       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.